Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.77B |
| 2 |
McKesson
MCK
|
+$2.38B |
| 3 |
SpaceX
SPCX
|
+$2.3B |
| 4 |
HONA
Honeywell Aerospace
HONA
|
+$2.05B |
| 5 |
Amazon
AMZN
|
+$1.37B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.96B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$3.11B |
| 3 |
Honeywell
HON
|
+$1.96B |
| 4 |
Salesforce
CRM
|
+$1.47B |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$775M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.02% |
| 2 | Technology | 24.63% |
| 3 | Financials | 9.78% |
| 4 | Healthcare | 7.32% |
| 5 | Industrials | 7.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
6276
Innovator S&P Investment Grade Preferred ETF
EPRF
$63.7M
| $61.2K | ﹤0.01% |
3,712
+1
| +0% | +$17 |
2022 Q3
15 quarters
|
|
6277
Roadzen
RDZN
$96.2M
| $60.7K | ﹤0.01% |
41,597
+24,097
| +138% | +$38.2K |
2024 Q2
8 quarters
|
|
|
MGN
6278
Megan Holdings Ltd
MGN
$4.53M
| $60.5K | ﹤0.01% |
+13,333
| New | +$69.1K |
2026 Q2
0 quarters
|
|
6279
Alpha Tau Medical Warrant
DRTSW
$91.8M
| $60.4K | ﹤0.01% |
20,475
| – | – |
2025 Q4
2 quarters
|
|
6280
Core Scientific Inc Tranche 1 Warrants
CORZW
$860M
| $60.3K | ﹤0.01% |
3,208
+3,055
| +1,997% | +$51.4K |
2024 Q1
9 quarters
|
|
6281
SP Funds S&P 500 Sharia ETF
SPUS
$3.37B
| $60.2K | ﹤0.01% |
1,046
-248
| -19% | -$13.7K |
2023 Q1
13 quarters
|
|
6282
FT Vest US Equity Enhance & Moderate Buffer ETF June
XJUN
$139M
| $60.1K | ﹤0.01% |
1,353
| – | – |
2025 Q2
4 quarters
|
|
6283
FT Vest US Equity Moderate Buffer ETF October
GOCT
$255M
| $60K | ﹤0.01% |
1,445
| – | – |
2026 Q1
1 quarter
|
|
6284
BondBloxx JPMorgan USD Emerging Markets 1-10 Year Bond ETF
XEMD
$964M
| $60K | ﹤0.01% |
1,336
+227
| +20% | +$10.2K |
2023 Q4
10 quarters
|
|
6285
Sui Group Holdings
SUIG
$108M
| $59.7K | ﹤0.01% |
51,500
| – | – |
2025 Q3
3 quarters
|
|
6286
Themes Global Systemically Important Banks ETF
GSIB
$41.4M
| $59.6K | ﹤0.01% |
1,000
| – | – |
2025 Q3
3 quarters
|
|
|
SVA
6287
DELISTED
Sinovac Biotech, Ltd
SVA
| $59.2K | ﹤0.01% |
9,146
+2
| +0% | +$13 |
2025 Q2
4 quarters
|
|
6288
iShares MSCI China Small-Cap ETF
ECNS
$61.8M
| $59.1K | ﹤0.01% |
2,100
-5,547
| -73% | -$178K |
2013 Q2
52 quarters
|
|
6289
Hartford Schroders Tax-Aware Bond ETF
HTAB
$228M
| $59.1K | ﹤0.01% |
3,080
+6
| +0.2% | +$115 |
2023 Q3
11 quarters
|
|
6290
FT Vest Growth-100 Buffer ETF March
QMAR
$615M
| $59.1K | ﹤0.01% |
1,587
| – | – |
2024 Q3
7 quarters
|
|
6291
IZEA Worldwide
IZEA
$40.1M
| $59K | ﹤0.01% |
15,943
| – | – |
2016 Q1
41 quarters
|
|
6292
Amplify Lithium & Battery Technology ETF
BATT
$112M
| $58.8K | ﹤0.01% |
3,823
+1,491
| +64% | +$24.6K |
2020 Q4
22 quarters
|
|
6293
Xtrackers FTSE Developed ex US Multifactor ETF
DEEF
$54.5M
| $58.6K | ﹤0.01% |
1,516
-1,338
| -47% | -$52.5K |
2018 Q2
32 quarters
|
|
6294
Super Hi International Holding
HDL
$700M
| $58.5K | ﹤0.01% |
5,021
-11
| -0.2% | -$150 |
2024 Q3
7 quarters
|
|
6295
Innovator US Equity Ultra Buffer ETF November
UNOV
$108M
| $58.1K | ﹤0.01% |
1,447
+467
| +48% | +$18.4K |
2025 Q4
2 quarters
|
|
6296
CSP Inc
CSPI
$74.2M
| $57.8K | ﹤0.01% |
7,282
+1,048
| +17% | +$9.57K |
2020 Q4
22 quarters
|
|
6297
SGI Dynamic Tactical ETF
DYTA
$110M
| $57.7K | ﹤0.01% |
+1,816
| New | +$55.5K |
2026 Q2
0 quarters
|
|
6298
enGene Therapeutics
ENGN
$116M
| $57.2K | ﹤0.01% |
33,086
-53,514
| -62% | -$218K |
2023 Q4
10 quarters
|
|
6299
American Realty Investors
ARL
$266M
| $57.2K | ﹤0.01% |
2,568
+897
| +54% | +$13.4K |
2015 Q3
43 quarters
|
|
6300
Vanguard US Quality Factor ETF
VFQY
$500M
| $57K | ﹤0.01% |
335
| – | – |
2023 Q2
12 quarters
|
|
Similar funds
Morgan Stanley's Q2 2026 Portfolio in Review
As of Q2 2026, Morgan Stanley held 8,715 positions worth $1.89T, up 14% from $1.66T the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Morgan Stanley's Q2 2026 filing shows 425 new, 3,807 increased, 3,215 reduced and 303 closed positions. Its largest new stake was SpaceX: 13,532,773 shares worth $2.31B. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $5.96B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Financials.
- Morgan Stanley's largest Q2 2026 buy was SpaceX: 13,532,773 shares worth $2.31B.
- Morgan Stanley added most to NVIDIA in Q2 2026, an estimated $2.77B increase.
- Morgan Stanley's biggest Q2 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.96B.
- Morgan Stanley fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $404M.
- Morgan Stanley's ten largest holdings make up 21% of its $1.89T portfolio in Q2 2026.
- Morgan Stanley opened 425 new positions and closed 303 in Q2 2026.
- Morgan Stanley's portfolio value rose 14% quarter-over-quarter to $1.89T.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.